-
Mashup Score: 0Harnessing Recombinant Human Polyclonal Antibodies for Potential HBV Treatment, Cure - 9 month(s) ago
A company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b (HBV).
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Identifying COVID-19 Risk Factors: Insights From 4 Vaccine Trials - 10 month(s) ago
Workplace exposure and living conditions were associated with higher COVID-19 risk, while previous infection, age 65 or older, and Black/African American race were correlated with lower COVID-19 rates.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
An analysis of 4 COVID-19 vaccine trials sheds light on the factors influencing COVID-19 outcomes. Workplace exposure and living conditions raise the risk, while prior infection, age 65+, and being Black/African American offer some protection. https://t.co/X03UGWTfK2
-
-
Mashup Score: 0Hospital Modifies Testing for C difficile to Ascertain Actual Rate of Hospital-Acquired Infection - 10 month(s) ago
Hospital posits that testing for C diff in patients without symptoms inflates rate of hospital-acquired infection with cases of asymptomatic colonization.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
Testing for #Cdiff in patients without symptoms can inflate rates of hospital-acquired infection. #IDtwitter #MedTwitter https://t.co/kGICAgfJKf
-
-
Mashup Score: 0Examining Vitamin D’s Role in Preventing C diff - 10 month(s) ago
A new study looks at vitamin D’s role in acting as a deterrent to the proliferation of C diff bacteria.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
A team of scientists at @Rutgers_NJMS delved into the relationship between #vitaminD and #Cdiff https://t.co/IyUiiNytF2
-
-
Mashup Score: 2These Factors Increase the Risk of “Long COVID” in Children - 10 month(s) ago
More symptoms, older age, and longer hospitalization time increased the risk of post-COVID-19 conditions (long COVID) in children.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
Post-COVID-19 conditions can affect children too, according to a new study. Discover the concerning findings and the importance of understanding and addressing long COVID in pediatric populations. https://t.co/CkvqH1xiDE
-
-
Mashup Score: 2New Funding Budget Cuts HIV Programs - 10 month(s) ago
A congressional subcommittee aims at reducing HIV-related budget items by over half a billion dollars.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
A congressional subcommittee aims at reducing #HIV -related budget items by over half a billion dollars. @HIVHep reminds the public and Congress of the need to continue funding for the initiative Ending the HIV Epidemic as well as other HIV programs. https://t.co/WUOgpZk6T6
-
-
Mashup Score: 0Weekly Recap: The Infectious Disease News You Missed - 10 month(s) ago
Which COVID-19 vaccine is associated with Guillain-Barré Syndrome? What’s the newest C difficile therapy? Contagion’s weekly infectious disease recap has you covered.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
📢 Stay informed with our Weekly Recap of infectious disease news! From breakthrough C diff treatments to malaria outbreaks in the US, we've got you covered. Don't miss out on the updates that matter. https://t.co/T0mXPGPPTx https://t.co/z9abvEtH5Q
-
-
Mashup Score: 0Investigational C diff Antibody Takes Novel Mechanism of Action Approach - 10 month(s) ago
Lumen Bioscience’s C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
.@LumenBio CEO @Finrow discusses his company's investigational #cdiff therapy being studied for prevention and treatment of the healthcare-associated infection. #IDtwitter #MedTwitter https://t.co/h8V7S58lvQ
-
-
Mashup Score: 0
In a major breakthrough, Gilead’s remdesivir (Veklury) becomes the first COVID-19 antiviral to be FDA-approved for patients with severe renal disease.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
#BreakingNews: The FDA has approved remdesivir as the first and only antiviral COVID-19 treatment for patients with severe renal impairment. Learn more about this breakthrough and how it benefits those with kidney disease. https://t.co/rea7mV6iAK
-
-
Mashup Score: 0How COVID-19 Infiltrates and Inflames the Heart - 10 month(s) ago
Neuropilin-1 enables COVID-19 to enter human cardiomyocytes, accounting for increased proteases activity and apoptotic markers that lead to cell damage and apoptosis.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
Unveiling the Impact of COVID-19 on the Heart! Dive into the findings of this study, exploring the role of proteolytic activity, inflammation, and oxidative stress in COVID-19-related cardiac damage. https://t.co/T0cjEgGLcG
-
Carter Keller @gigageninc discusses his company's platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for #hepatitisB. #livertwitter https://t.co/L1HikI029V https://t.co/v4CTqZrDXp